Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AM
Amphastar Pharmaceuticals, Inc.
AMPH
Mkt Cap
$1.10B
Volume
276.15K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AM
AMPH
AM
Amphastar Pharmaceuticals, Inc.
AMPH
News
·
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Mkt Cap
$1.12B
Volume
276.15K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Insider
Filings
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Zacks highlights Amphastar Pharmaceuticals (AMPH) as an attractive value stock with a Zacks Rank #2 (Buy) rating and an 'A' grade for Value. The stock trades at a P/E ratio of 7.81 compared to its industry average of 15.87, along with favorable P/B and P/S ratios, suggesting it is currently undervalued by the market.
Zacks Investment Research · Oct 6, 2026
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris
The generic drug industry shows mixed but resilient performance with companies focusing on operational efficiency and portfolio optimization. Three standout stocks—Amphastar Pharmaceuticals, Sandoz, and Viatris—are well-positioned to capitalize on industry evolution through new product launches, biosimilar expansion, and complex generics development. However, the industry faces persistent pricing pressure and competition, with the Zacks Medical-Generic Drugs industry ranked #160 out of 247 industries.
Zacks Investment Research · Aug 31, 2026
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
The generic drug industry is experiencing a mixed but resilient operating environment with pricing pressures offset by healthy underlying demand and new product launches. Three companies—Amphastar Pharmaceuticals, Sandoz, and Viatris—are well-positioned to capitalize on industry evolution through biosimilar expansion, complex generics development, and operational efficiency improvements. The industry currently trades at a valuation discount compared to broader market indices.
Zacks Investment Research · Aug 27, 2026
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs
The Trump administration will exclude imported generic drugs from potential tariffs, bringing relief to pharmaceutical companies and Indian drugmakers who supply nearly half of U.S. generic prescriptions.
Benzinga · Oct 9, 2025
Global Antidote Market to Cross the USD 4 Billion Mark by 2032 | DelveInsight
The dilated cardiomyopathy market is witnessing substantial growth, driven by advancements in cardiovascular therapies and the increasing incidence of the condition. Key factors contributing to the market's upward momentum include greater public awareness, government initiatives, and continuous progress in product innovation.
GlobeNewswire Inc. · Jun 5, 2025
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
The specialty pharma sector is showing signs of stability, with modest growth and valuations recovering to historical averages. JP Morgan is most interested in Teva and Organon, maintaining a neutral rating on Teva due to its branded pipeline and caution about its U.S. generic business, while giving an underweight rating to Organon due to its recent stock price surge.
Benzinga · Sep 6, 2024
HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2024 EPS View - Zacks Investment Research
HCA Healthcare reported strong Q2 2024 results, with adjusted EPS of $5.50 beating estimates and revenues of $17.5 billion growing 10.3% year-over-year. The company benefited from rising admissions and higher inpatient and outpatient surgeries, though rising expenses partially offset the positives.
Zacks Investment Research · Jul 23, 2024
Amphastar Pharmaceuticals: Buy When Fear Is Overblown
Amphastar Pharmaceuticals' stock has fallen 31% in 5 months despite positive financials, and whether it presents a value investment. Read more here.
Seeking Alpha · May 30, 2024
Implied Volatility Surging for Amphastar (AMPH) Stock Options
Investors need to pay close attention to Amphastar (AMPH) stock based on the movements in the options market lately.
Zacks Investment Research · May 15, 2024
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings and Revenue Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of 35.06% and 0.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 8, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AM
AMPH
Amphastar Pharmaceuticals, Inc.
Buy
Sell
Market
Limit
Soon
AMPH
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any AMPH yet.
Related Tickers
Earnings